JOVIC, Gordana
 Distribuzione geografica
Continente #
NA - Nord America 3.000
EU - Europa 1.480
AS - Asia 1.281
SA - Sud America 183
AF - Africa 40
Continente sconosciuto - Info sul continente non disponibili 31
OC - Oceania 2
Totale 6.017
Nazione #
US - Stati Uniti d'America 2.934
SG - Singapore 458
GB - Regno Unito 319
CN - Cina 295
IT - Italia 288
SE - Svezia 204
IE - Irlanda 190
VN - Vietnam 132
HK - Hong Kong 129
BR - Brasile 128
DE - Germania 127
RU - Federazione Russa 72
FI - Finlandia 68
BD - Bangladesh 66
UA - Ucraina 63
FR - Francia 51
TR - Turchia 39
IN - India 37
CA - Canada 34
LT - Lituania 22
BG - Bulgaria 21
AR - Argentina 19
KR - Corea 19
ID - Indonesia 15
JP - Giappone 15
NL - Olanda 14
MX - Messico 13
IQ - Iraq 12
ZA - Sudafrica 11
AE - Emirati Arabi Uniti 10
CO - Colombia 9
EC - Ecuador 9
ES - Italia 8
ET - Etiopia 8
PH - Filippine 8
PK - Pakistan 7
CL - Cile 6
EG - Egitto 6
PL - Polonia 6
MY - Malesia 5
SA - Arabia Saudita 5
IR - Iran 4
JO - Giordania 4
KE - Kenya 4
PT - Portogallo 4
RS - Serbia 4
SN - Senegal 4
UZ - Uzbekistan 4
VE - Venezuela 4
AL - Albania 3
BE - Belgio 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
PY - Paraguay 3
TW - Taiwan 3
AU - Australia 2
BO - Bolivia 2
GR - Grecia 2
GT - Guatemala 2
HU - Ungheria 2
IL - Israele 2
LB - Libano 2
MA - Marocco 2
PA - Panama 2
PR - Porto Rico 2
TH - Thailandia 2
UY - Uruguay 2
AO - Angola 1
AT - Austria 1
AZ - Azerbaigian 1
BB - Barbados 1
BY - Bielorussia 1
BZ - Belize 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
HN - Honduras 1
JM - Giamaica 1
KH - Cambogia 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LV - Lettonia 1
ME - Montenegro 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
ST - Sao Tome e Principe 1
TJ - Tagikistan 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.987
Città #
Singapore 313
Ashburn 298
Santa Clara 256
Fairfield 219
Southend 201
Dublin 188
Chandler 182
Woodbridge 156
San Jose 143
Houston 136
Hong Kong 121
Dearborn 118
Nyköping 109
Jacksonville 100
Beijing 94
Seattle 86
Cambridge 81
Council Bluffs 81
Wilmington 71
New York 70
Ann Arbor 68
Los Angeles 59
London 55
Helsinki 45
Ho Chi Minh City 41
Milan 38
Chicago 35
Hanoi 30
Munich 27
San Diego 27
The Dalles 26
Modena 25
Izmir 24
Princeton 22
Columbus 19
Eugene 19
Hefei 19
Rome 19
Sofia 19
Lauterbourg 17
Moscow 16
Salt Lake City 15
Shanghai 15
Dallas 13
Jakarta 13
Seoul 13
Denver 12
Dong Ket 12
Palermo 12
Des Moines 11
Lansdale 11
Phoenix 11
Buffalo 10
Springfield 10
Boardman 9
Da Nang 9
Guangzhou 9
Tampa 9
Turku 9
York 9
Brooklyn 8
Orem 8
Reading 8
Tokyo 8
Atlanta 7
Bologna 7
Bremen 7
Chengdu 7
Chennai 7
Stockholm 7
Toronto 7
Frankfurt am Main 6
Montreal 6
Naples 6
Rio de Janeiro 6
Baghdad 5
Charlotte 5
Elk Grove Village 5
Guayaquil 5
Johannesburg 5
Kunming 5
Miami 5
Mumbai 5
Nanjing 5
Porto Alegre 5
Redondo Beach 5
São Paulo 5
Tulsa 5
Warsaw 5
Amman 4
Amsterdam 4
Ankara 4
Bari 4
Belo Horizonte 4
Dakar 4
Falls Church 4
Gallarate 4
Hải Dương 4
Kyiv 4
Norwalk 4
Totale 4.104
Nome #
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 435
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 413
Helicobacter pylori infection andchronic immune thrombocytopenic purpura: long-term results of bacteriumeradication and association with bacterium virulence profiles 412
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 394
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 389
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 384
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 382
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 332
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 325
Middle turbinate preservation versus middle turbinate resection in endoscopic surgical treatment of nasal polyposis 320
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 315
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 281
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 278
Biomarker expression and survival after primary chemotherapy for breast cancer. 257
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 250
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 245
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability 221
CHEMOTHERAPY-INDUCED MODULATION OF BIOMARKERS EXPRESSION IN PRIMARY BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 192
Final results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarker evaluation in operable breast cancer 192
Totale 6.017
Categoria #
all - tutte 20.756
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.756


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022335 0 0 59 23 10 32 24 13 39 17 75 43
2022/2023679 88 82 32 56 45 59 21 36 215 4 8 33
2023/2024379 18 22 22 29 81 45 23 55 16 9 33 26
2024/2025891 28 21 10 79 169 151 52 59 121 39 61 101
2025/20261.891 102 47 109 229 409 116 215 80 176 196 138 74
2026/2027193 59 127 7 0 0 0 0 0 0 0 0 0
Totale 6.017